CTOs on the Move

Sprout Pharmaceuticals

www.sproutpharma.com

 
We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.sproutpharma.com
  • 4350 Lassiter at North Hills Avenue Suite 260
    Raleigh, NC USA 27609
  • Phone: 919.882.0850

Executives

Name Title Contact Details

Funding

Sprout Pharmaceuticals raised $20M on 09/04/2019

Similar Companies

Hope Clinic

Hope Clinic is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantum Group

Quantum Group is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Quantum Group is based in Wellington, FL. You can find more information on Quantum Group at www.quantummd.com

Middle Peninsula-Northern Neck Community Services Board

The Middle Peninsula Northern Neck Community Services Board is a public, nonprofit organization providing services to meet the needs of individuals and their families who have problems associated with mental health, intellectual disabilities, substance abuse, and developmental disabilities. Services are provided to residents in the Middle Peninsula and Northern Neck, VA. This area includes the counties of Westmoreland, Richmond, Essex, Northumberland, Lancaster, Gloucester, Mathews, Middlesex King & Queen and King William. It also includes the Town of Colonial Beach and West Point.

China Aoxing Pharmaceutical Company

China Aoxing Pharmaceutical Company is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.